AstraZeneca’s Chinese operation is under intense scrutiny by the National Healthcare Security Administration of China over concerns about suspected medical insurance fraud perpetrated by company employees.
According to a statement from China’s NHSA, AstraZeneca staff members are suspected of tampering with the genetic testing results of cancer patients in order to defraud medical insurance funds. Following an investigation conducted by the Chinese government, several AstraZeneca employees have been arrested. The government report did not detail the fraud, nor did it provide additional information as to the goal of the perpetrators.
AstraZeneca China, the company’s business operations in that country, confirmed the arrest of the employees. In a statement issued over the weekend, AstraZeneca China said it conducted its own internal compliance investigation that revealed “a few of its employees in Shenzhen city” had “altered or participated in altering patients’ testing reports.” By altering those reports, the employees were committing medical insurance fraud, the company said.
AstraZeneca said it took “serious disciplinary action” against the employees and is cooperating with the government investigation.
The Chinese government has demanded that AstraZeneca “close loopholes” in its marketing supervision, as well as conduct in-house training to ensure that employees are abiding by the local laws.
Concerns about the insurance fraud were first raised at the end of 2021....
You don't have permission to access "http://www.wltx.com/article/news/local/insurance-fraud-investigation-south-carolina-sled/101-bcab3639-c001-419a-b312-1a252d5721c5" on this server. Reference #1...